Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (5): 89-94.doi: 10.6040/j.issn.1671-7554.0.2024.0212

• Clinical Medicine • Previous Articles    

Intratumor heterogeneity of SP1 expression in colorectal cancer and its clinical significance

WEI Yanruoxue1, LI Ziqi1, LIU Chuncheng1, LIU Xiaohan1, ZHAO Ran1,2, LIU Yukun1,2   

  1. 1. Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. Department of Pathology, Affiliated Hospital of Jining Medical University, Jining 272029, Shandong, China
  • Published:2024-05-29

PDF (PC)

57

Abstract: Objective To investigate the intratumor heterogeneity(ITH)of specificity protein 1(SP1)protein expression in colorectal cancer(CRC)and its clinical significance. Methods Clinical specimens of CRC were collected. The expression level and pattern of SP1 protein were detected by immunohistochemical EnVision method. The ITH characteristics of SP1 protein expression were identified, and the ITH level of SP1 protein was defined. The relationship between ITH level of SP1 protein and clinicopathological characteristics and prognosis of CRC patients was analyzed. Results SP1 protein showed typical ITH expression in CRC. The ITH level of SP1 protein was associated with lymph node metastasis(P<0.001)and TNM stage(P<0.001). Survival analysis showed that the overall survival(OS)of patients with high ITH level of SP1 protein was significantly lower than that with low ITH level(61.25% vs 81.82%, P=0.004). Univariate and multivariate Cox regression analyses showed that high SP1 protein ITH was an independent predictor of poor OS in CRC patients(HR=2.680, P=0.017). Conclusion The expression of SP1 protein in CRC has significant ITH characteristics, and defines the quantitative criteria of SP1 ITH level for the first time. It is demonstrated that a high ITH level of SP1 protein is significantly associated with CRC progression and poor prognosis.

Key words: Colorectal cancer, SP1 protein, Intratumor heterogeneity, Immunohistochemistry, Prognosis

CLC Number: 

  • R735.3
[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2] Lu Z, Chen Y, Liu D, et al. The landscape of cancer research and cancer care in China [J]. Nat Med, 2023, 29(12): 3022-3032.
[3] Du L, Cheng Q, Zheng H, et al. Targeting stemness of cancer stem cells to fight colorectal cancers [J]. Semin Cancer Biol, 2022, 82: 150-161. doi: 10.1016/j.semcancer.
[4] Jiang M, Jin S, Han J, et al. Detection and clinical significance of circulating tumor cells in colorectal cancer [J]. Biomark Res, 2021, 9(1): 85. doi: 10.1186/s40364-021-00326-4.
[5] Pietropaolo G, Scarno G, Stabile H, et al. NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data [J]. Mol Aspects Med, 2021, 80: 100967. doi: 10.1016/j.mam.2021.100967.
[6] Crucitta S, Cucchiara F, Mathijssen R, et al. Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours [J]. Cancer Treat Rev, 2022, 104: 102340. doi: 10.1016/j.ctrv.2022.102340.
[7] Mauri G, Vitiello PP, Sogari A, et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer [J]. Br J Cancer, 2022, 127(3): 394-407.
[8] Al Zein M, Boukhdoud M, Shammaa H, et al. Immunotherapy and immunoevasion of colorectal cancer [J]. Drug Discov Today, 2023, 28(9): 103669. doi: 10.1016/j.drudis.2023.103669.
[9] Zhang GP, Xie ZL, Jiang J, et al. Mechanical confinement promotes heat resistance of hepatocellular carcinoma via SP1/IL4I1/AHR axis [J]. Cell Rep Med, 2023, 4(8): 101128. doi: 10.1016/j.xcrm.2023.101128.
[10] Zhang M, Kan D, Zhang B, et al. P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC [J]. J Exp Clin Cancer Res, 2023, 42(1): 215. doi: 10.1186/s13046-023-02777-z.
[11] Zhao G, Yuan H, Li Q, et al. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2 [J]. Signal Transduct Target Ther, 2022, 7(1): 275. doi: 10.1038/s41392-022-01096-7.
[12] Zhu Z, Guo Y, Liu Y, et al. ELK4 Promotes colorectal cancer progression by activating the neoangiogenic factor LRG1 in a noncanonical SP1/3-dependent manner [J]. Adv Sci(Weinh), 2023, 10(32): e2303378. doi: 10.1002/advs.202303378.
[13] Fosso E, Leo M, Muccillo L, et al. Quercetins dual mode of action to counteract the Sp1-miR-27a axis in colorectal cancer cells [J]. Antioxidants(Basel), 2023, 12(8): 1547. doi: 10.3390/antiox12081547.
[14] Tang T, Fang D, Ji Z, et al. Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells [J]. Cell Oncol(Dordr), 2023. doi: 10.1007/s13402-023-00887-6.
[15] Liu J, Zhan W, Chen G, et al. SP1-induced PROX1-AS1 contributes to tumor progression by regulating miR-326/FBXL20 axis in colorectal cancer [J]. Cell Signal, 2023, 101: 110503. doi: 10.1016/j.cellsig.2022.110503.
[16] Kahn AM, Golestani R, Harigopal M, et al. Intratumor spatial heterogeneity in programmed death-ligand 1(PD-L1)protein expression in early-stage breast cancer [J]. Breast Cancer Res Treat, 2023, 201(2): 289-298.
[17] Ge LP, Jin X, Ma D, et al. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer [J]. Cell Res, 2024, 34(1): 58-75.
[18] Geng K, Merino LG, Veiga RG, et al. Intrinsic deletion at 10q23.31, including the PTEN gene locus, is aggravated upon CRISPR-Cas9-mediated genome engineering in HAP1 cells mimicking cancer profiles [J]. Life Sci Alliance, 2023, 7(2): e202302128. doi: 10.26508/lsa.202302128.
[19] Tornesello ML, Cerasuolo A, Starita N, et al. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations [J]. Front Cell Dev Biol, 2023, 11: 1286683. doi: 10.3389/fcell.2023.1286683.
[20] Enikeeva K, Rafikova G, Sharifyanova Y, et al. Epigenetics as a key factor in prostate cancer [J]. Adv Biol(Weinh), 2024, 20: e2300520. doi: 10.1002/adbi.202300520.
[21] Gasperoni JG, Fuller JN, Darido C, et al. Grainyhead-like(Grhl)target genes in development and cancer [J]. Int J Mol Sci, 2022, 23(5): 2735. doi: 10.3390/ijms23052735.
[22] He W, Hong X, Chen G, et al. RNA modifications in gynecological cancer: current status and future directions [J]. Front Med(Lausanne), 2024, 11: 1314075. doi: 10.3389/fmed.2024.1314075.
[23] Su X, Lu R, Qu Y, et al. Diagnostic and therapeutic potentials of methyltransferase-like 3 in liver diseases [J]. Biomed Pharmacother, 2024, 172: 116157. doi: 10.1016/j.biopha.2024.116157.
[24] Peng N, Liu J, Hai S, et al. Role of post-translational modifications in colorectal cancer metastasis [J]. Cancers(Basel), 2024, 16(3): 652. doi: 10.3390/cancers16030652.
[25] Taylor BC, Sun X, Gonzalez-Ericsson PI, et al. NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple negative breast cancer [J]. Cancer Discov, 2024, 14(2): 290-307.
[26] Corpetti M, Müller C, Beltran H, et al. Prostate-specific membrane antigen-targeted therapies for prostate cancer: towards improving therapeutic outcomes [J]. Eur Urol, 2024, 85(3): 193-204.
[27] Wang Y, Zhou Y, Yang L, et al. Challenges coexist with opportunities: spatial heterogeneity expression of PD-L1 in cancer therapy [J]. Adv Sci(Weinh), 2024, 11(1): e2303175. doi: 10.1002/advs.202303175.
[28] Valenza C, Guidi L, Battaiotto E, et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers [J]. Trends Cancer, 2024, 10(2): 113-123.
[1] LIU Chuncheng, LIU Xiaohan, WEI Yanruoxue, LI Ziqi, LIU Yukun, ZHAO Ran. Subcellular localization pattern of bromodomain containing 9 in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 24-30.
[2] WU Lin, SHI Chenxi, TONG Xing. Pulmonary benign metastasizing leiomyoma: a report of 7 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 78-84.
[3] YANG Xueyan, WU Yinping, LYU Li, ZHAO Zehua, MA Hangyu, LI Fengcai, WANG Kai, FAN Yuchen. Diagnostic value of dynamic changes of monocyte-to-lymphocyte ratio in acute-on-chronic hepatitis B liver failure [J]. Journal of Shandong University (Health Sciences), 2024, 62(3): 61-69.
[4] DIAO Yujie, LIN Lin, LI Wenxuan, WANG Zhouyang, JIANG Bei, HU Yingying, LIU Guangyi. Neutrophil-to-platelet ratio predicts adverse renal outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis and its synergistic multifactor optimization model [J]. Journal of Shandong University (Health Sciences), 2024, 62(2): 60-68.
[5] JING Kai, XU Zhiwei, LI Leping. Exploring colorectal cancer related genes and their functions based on GEO [J]. Journal of Shandong University (Health Sciences), 2024, 62(1): 21-30.
[6] DONG Yaqi, WANG Xinhui, ZHAO Yinghui, WANG Chuanxin. Clinical value of serum exosomal LINC02163 as a marker for distant metastasis of colorectal cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(9): 19-28.
[7] FAN Rong, LI Binbin, MA Xiaoli, WANG Yunshan, JIA Yanfei. Expressions and clinical significance of DEC2 and HIF-2α in gastric cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(7): 12-18.
[8] LIU Yan, LENG Shanshan, XIA Xiaona, DONG Hao, HUANG Chencui, MENG Xiangshui. Functional outcomes of 376 patients with supratentorial spontaneous intracerebral hemorrhage based on radiomic parameters [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 59-67.
[9] CHEN Rong, YANG Yue, YANG Zhixiang, SU Yaying, PANG Zhiying, WANG Dawei, CUI Shujun, YANG Fei. Texture analysis based on CT to predict the short-term outcomes of acute pulmonary embolism [J]. Journal of Shandong University (Health Sciences), 2023, 61(12): 78-85.
[10] HUA Yuefan, HE Keyao, ZHANG Jiahao, QIAN Mengfan, LIU Yiwen, KONG Jinyu, YANG Haijun, ZHOU Fuyou. Effects of high expressions of hypoxia inducible factor-1 and vascular endothelial growth factor induced by Fusobacterium nucleatum on survival and prognosis of patients with esophageal squamous cell carcinoma [J]. Journal of Shandong University (Health Sciences), 2023, 61(11): 59-67.
[11] ZHAO Qidi, WANG Kai, ZHAO Xiaogang, YAN Tao, WANG Yadong, DU Jiajun. Constructing and validating a prognostic model for patients with stage IIIB non-small cell lung cancer based on SEER database [J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 23-37.
[12] ZHENG Su, CHEN Shuhua, LI Hua, DENG Jie, CHEN Chunhong, WANG Xiaohui, FENG Weixing, HAN Xiaodi, ZHANG Yujia, LI Na, LI Mo, FANG Fang. Correlation between EEG variations and BASED evaluation of the efficacy of ACTH treatment in 54 cases of infantile spasms [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 91-96.
[13] WANG Lihui, GAO Min, KONG Beihua. Angiosarcoma of the uterus: a report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 108-112.
[14] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[15] ZHANG Yufeng, XU Min, XING Xiuli, PANG Shuguang, HU Keqing. Epidemiological characteristics of 689 patients with non-ST-segment elevation myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 118-122.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd